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Abstract
Background
Recent studies in multiple sclerosis (MS) showed longer survival times from clinical onset
than older hospital-based series. However estimated median time ranges widely, from 24 to
45 years, which makes huge difference for patients as this neurological disease mainly
starts around age 20 to 40. Precise and up-to-date reference data about mortality in MS are
crucial for patients and neurologists, but unavailable yet in France.
Objectives
Estimate survival in MS patients and compare mortality with that of the French general
population.
Methods
We conducted a multicenter observational study involving clinical longitudinal data from
30,413 eligible patients, linked to the national deaths register. Inclusion criteria were definite
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MS diagnosis and clinical onset prior to January, 1st 2009 in order to get a minimum of 1-
year disease duration.
Results
After removing between-center duplicates and applying inclusion criteria, the final popula-
tion comprised 27,603 MS patients (F/M sex ratio 2.5, mean age at onset 33.0 years, 85.5%
relapsing onset). During the follow-up period (mean 15.2 +/- 10.3 years), 1569 deaths
(5.7%) were identified; half related to MS. Death rates were significantly higher in men,
patients with later clinical onset, and in progressive MS. Overall excess mortality compared
with the general population was moderate (Standardized Mortality Ratio 1.48, 95% confi-
dence interval [1.41-1.55]), but increased considerably after 20 years of disease (2.20
[2.10-2.31]).
Conclusions
This study revealed a moderate decrease in life expectancy in MS patients, and showed
that the risk of dying is strongly correlated to disease duration and disability, highlighting the
need for early actions that can slow disability progression.
Introduction
A number of studies of mortality in multiple sclerosis (MS) have been conducted over the past
20 years, with more or less consistent results. Reported median survival times fromMS clinical
onset ranged from 24 to 45 years [1–16], with longer durations in more recent studies. Mortal-
ity in MS is of particular interest, as this neurological disease mainly affects young adults, most
cases starting between age 20 and 40. All series have revealed excess mortality (1.3 to threefold)
and reduced life expectancy (range: 6-14 years) in MS patients compared with the general pop-
ulation [1–11, 17, 18]. A lower age at onset is associated with a better prognosis, while results
on sex remain controversial. The acknowledged increase in the female/male sex ratio (from 2:1
to nearly 3:1) is linked to the increased incidence among women [19–21], but may also raise
the question of its potential relationship to differential survival between men and women, i.e. a
better survival in women than in men.
In 2004, we carried out a study of 1879 French MS patients [5] that confirmed most results
of the literature, although the standardized mortality ratio (SMR) was surprisingly low (1.3,
95% CI [1.0–1.7]). Several limitations may have accounted for this striking difference, includ-
ing a short follow-up duration (13 years) and therefore a relatively youthful and low-disabled
population at the end-of-study date. Indeed, in natural history studies, the median time to
need walking aid is estimated to be around 20 to 25 years fromMS clinical onset [22, 23].
There was also a potential selection bias, as patients were enrolled from a single MS referral
center located in Rennes in Brittany region, Western France.
We therefore decided to initiate a large-scale multicenter study of mortality in MS in France,
with the aim of measuring death rates and life expectancy in patients, describing causes of
death, assessing prognostic factors for death, and comparing mortality in patients with the
French general population.
Mortality in Patients with Multiple Sclerosis in France
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Methods
Study population
Recruitment took place via the network of French users of EDMUS. Although EDMUS initially
was a software dedicated to MS that was developed in France in the 1990s [24], it now corre-
sponds to a large network of clinicians and researchers whose aim is to fight MS, by improving
care and promoting research. In the software, demographic, and longitudinal clinical data are
prospectively collected during each neurological appointment (some being retrospectively col-
lected during the first appointment) and can be used for both medical follow-up and research
purposes. A total of 15 MS centers agreed to participate in the present study, accounting for a
potential of 33,000 MS patients at study launch (i.e. about one third of prevalent MS cases in
France [25]). Inclusion criteria were defined as a definite diagnosis of MS according to either
Poser [26] or McDonald [27, 28] depending on the period of diagnosis, and clinical onset of
MS prior to January 1st 2009 in order to have a minimum disease duration of 1 year at the end-
of-study date, which was set as January 1st 2010.
Each EDMUS database has been approved by the French data protection authority (‘Com-
mission Nationale Informatique et Libertés’, CNIL). Furthermore, in accordance with French
legislation, the present study was approved before its start by both the CNIL (Approval DR-
2010-367) and the French advisory committee for data processing in health research (‘Comité
Consultatif du Traitement de l’Information en matière de Recherche dans le domaine de la
Santé, CCTIRS; Approval 10191). Those approvals were needed to link our dataset to the
national registers containing death information. Then the data were analyzed anonymously.
Death ascertainment and causes of death
As deaths are not exhaustively registered in the EDMUS databases, the clinical dataset was
linked to two national registers. The first register was the national repertory for the identifica-
tion of physical persons (‘Répertoire National d’Identification des Personnes Physiques’,
RNIPP), where each individual born in France after 1890 is identified by sex, surname (maiden
name for women), date and place of birth. This allowed us to obtain up-to-date vital status. We
also obtained data from the national death register (‘INSERM-CepiDc’), which contains infor-
mation provided in death certificates from 1968, including the date, place and causes of death,
coded according to the International Classification of Diseases (World Health Organization).
The underlying causes of death were categorized as follows according to ICD codes: MS (ICD-
10 code G35), cancer, cardiovascular disease and stroke, infectious disease, respiratory disease,
neurological disease except MS, suicide, digestive disease, accidental death, other disease,
unspecified (e.g. cardiac arrest) or unknown (i.e. death certificate unavailable) causes.
Prognostic factors for death
The primary endpoint was death, and the following parameters were considered as potential
explanatory variables: age at MS clinical onset, sex, initial MS course, and period of MS onset.
The initial MS course was defined as either relapsing onset or progressive onset [29]. The
period of MS onset was categorized as< 1980, 1980-1989, 1990-1999, or 2000-2009.
Comparison with the French general population
We calculated the individual probability of death for every patient during follow-up using life
tables for the French general population, by sex and age for the period 1940–2009 (source:
French National Institute for Demographic Studies). We calculated the number of expected
deaths by summing the individual expected probabilities of death. In addition to the overall
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PLOS ONE | DOI:10.1371/journal.pone.0132033 July 6, 2015 3 / 12
comparison between MS patients and the French general population, we also ran comparisons
for patient subgroups (sex, age at MS clinical onset, initial MS course, follow-up duration,
period of MS onset, and center) using standardized mortality ratios (SMRs). The individual
expected probability of death was also used to draw the expected survival curve fromMS onset.
When comparing the expected curve with the observed one, the reduced survival time after MS
clinical onset can be estimated approximately.
Statistical analyses
Qualitative and quantitative variables are provided as numbers (percentage) and
means ± standard deviation (SD), respectively. We calculated overall and subgroup mortality
frequencies (number of deaths divided by number of patients; %) and mortality rates (number
of deaths divided by number of person-years (PY) of follow-up per 1,000 PY). Sensitivity analy-
sis was performed to estimate number of expected deaths in patients whose vital status was
missing. Differences between subgroups were assessed using t, Anova or Fisher’s exact tests
when appropriate. Kaplan-Meier estimates with log-rank tests were used to assess prognostic
factors for the time between clinical MS onset and death, followed by a multivariate Cox pro-
portional hazards model (backward method). As period of onset was closely linked to disease
duration, it was not considered in the multivariate analysis. SMRs were equal to the number of
observed deaths divided by the number of expected deaths. The 95% confidence limits of the
SMRs were estimated using the Poisson distribution. All statistical tests were two-tailed, and
statistical significance was set at the 5% level. Any missing data were excluded from the analy-
ses. Statistical analyses were performed using STATA 11.
Results
Study population characteristics
At study launch, 30,413 MS files were received from the 15 participating centers, equivalent to
29,430 MS patients after removal of between-centers duplicates. Then, 1,164 patients were
excluded for “possible MS” diagnosis and a further 663 because MS onset occurred after 2009.
The final study population size was 27,603 MS patients (Fig 1).
Mean follow-up duration was 15.2 ± 10.3 years fromMS clinical onset, and the total number
of patient-years of follow-up was 420,801. Mean age at last clinical information was 48.0 ± 10.3
years. Mean MS duration differed significantly according to age at MS onset (ANOVA F test,
p<10−4): 19.9 ± 13.0, 15.8 ± 10.4, and 11.8 ± 7.7 years in the< 20, 20-40, and 40 years
groups respectively. Furthermore, as expected, we found that the earlier the period of MS
onset, the longer the disease duration (33.3 ± 9.7, 22.6 ± 5.1, 13.5 ± 4.0, and 5.6 ± 2.7 years for
the< 1980, 1980-1989, 1990-1999, and 2000-2009 subgroups respectively, ANOVA F test,
p<10−4). A total of 4,607 patients (16.7%) had unknown vital status at the end-of-study date
because they were not found in the national repertory (‘RNIPP’). These patients were therefore
included in the analyses as censored alive at the date of their last clinical information. Their
mean follow-up duration was significantly lower than that of the patients with known vital sta-
tus (12.2 ± 10.4 vs. 15.9 ± 10.2 years, t test, p<10−4). Their characteristics compared with those
of died and alive patients are presented in Table 1.
Mortality
During the follow-up period, a total of 1,569 deaths occurred (5.7%; 3.7 per 1,000 PY) in 884
women and 685 men, at a median age of 56 years (range: 19-96) and the median disease dura-
tion was 20 years (range: 1–88) (Table 2). Kaplan-Meier estimates revealed that 89.6% [88.9-
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90.2] and 72.3% [70.4-74.1] of MS patients were still alive 25 and 40 years after clinical onset
respectively.
Causes of death
The underlying cause of death was known from the death certificates for 1338 dead patients,
and were as follows: MS (n = 700; 52.3%), cancer (n = 187; 14.0%), cardiovascular disease or
stroke (n = 126; 9.4%), infection (n = 67; 5.0%), suicide (n = 47; 3.5%), accident (n = 46; 3.4%),
neurological disease other than MS (n = 34; 2.5%), digestive disease (n = 28; 2.1%), respiratory
disease (n = 27; 2.0%), other cause (n = 40; 3.0%), and unspecified (n = 36; 2.7%). MS was men-
tioned as either underlying or contributive cause of death in 1017 death certificates (76.0%).
Out of the 231 unavailable death certificates, 2 patients had died abroad and 11 certificates
Fig 1. Flowchart of the study population. These patients had the classic characteristics of MS populations:
F/M sex ratio 2.47 (19,656/7,947); mean age at MS clinical onset 32.8 ± 10.6 years; and 85.5% relapsing-
onset MS (23,438/27,408; 195 missing values). As expected, mean age at onset was significantly higher and
F/M sex ratio lower for progressive onset MS than for relapsing-onset MS (41.8 ± 10.8 vs. 31.2 ± 9.7 years, t
test, p < 10−4, and 1.40 vs. 2.76, Fisher’s exact test, p < 10−4, respectively). MS = Multiple Sclerosis.
doi:10.1371/journal.pone.0132033.g001
Table 1. Comparison of demographic and clinical characteristics of patients with multiple sclerosis (MS) according to vital status at the end of the
study.
Vital status at the end of study
Variable Alive Dead Censored alive
N = 21,427 N = 1,569 N = 4,607
Sex
Male 6,152 (28.7%) 685 (43.7%) 1,110 (24.1%)
Female 15,275 (71.3%) 884 (56.3%) 3497 (75.9%)
Sex ratio F:M 2.5 1.3 3.2
Mean age at MS onset (± SD), years 32.4 ± 10.4 35.2 ± 11.8 35.9 ± 10.9
Mean age at last information (± SD), years 47.8 ± 12.5 56.4 ± 13.3 46.1 ± 13.1
Mean MS duration (± SD), years 15.5 ± 10.0 21.2 ± 11.7 12.2 ± 10.4
Initial MS course
Relapsing 18,517 (86.7%) 1,137 (72.6%) 3,784 (84.4%)
Progressive 2,841 (13.3%) 430 (27.4%) 699 (15.6%)
doi:10.1371/journal.pone.0132033.t001
Mortality in Patients with Multiple Sclerosis in France
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could not be found, while 218 patients were not found in the RNIPP registry (n = 4,607) even
though their medical files indicated that they were dead.
Table 2 shows the patients’ characteristics according to their cause of death (less frequent
categories collapsed into a broader “other causes” category). MS was the underlying cause of
nearly half the deaths (700/1,569), and death occurred after a median MS duration of 20 years,
at a median age of 56 years. Suicide was the category with the lowest age at death (median 46
years), shortest disease duration (median 12 years), and sex ratio closest to 1 (23 men and 24
women). In the cardiovascular disease or stroke category, the percentage of women was also
quite similar to that of men (F/M sex ratio 0.91), whereas it was considerably higher for can-
cer-related deaths (F/M sex ratio: 1.79). In all, 67 cancer-related deaths occurred in men (most
frequent: 23 lung, 6 colorectal), and 120 in women (most frequent: 28 breast, 21 lung, and 14
colorectal).
Prognostic factors
Univariate assessment of the prognostic factors for death revealed that the risk of death was
higher among men, patients with later clinical onset, those with primary progressive MS, and
those with MS onset in an earlier period. These results were confirmed using a Cox multivariate
analysis (Table 3).
Comparison with the French general population
The overall SMR was 1.48 (95% CI [1.41-1.55]), resulting in 48% excess mortality in MS
patients compared with the French general population. The survival curves (Fig 2) show that
survival in MS patients was similar to that of the general population for the first 20 years of the
disease. The two curves then begin to diverge, and the resulting gap can be estimated at around
Table 2. Characteristics of the 1569 deaths categorized by underlying cause of death.
Cause of death Number of
deaths (/1569)
(%)
F/M
sex
ratio
Median age in years
at MS clinical onset
(range)
Median age in
years at death
(range)
Median disease
duration in years at
death (range)
Number (%) of
patients with
relapsing onset
Total 1569 (100%) 884/
685
1.29
34.3 (6-72) 56.0 (19-96) 19.7 (1-88) 1.137 (72.5%)
MS 700 (44.6%) 380/
320
1.19
32.2 (10-72) 54.5 (22-88) 19.7 (1-63) 509 (72.8%)
Cancer 187 (11.8%) 120/67
1.79
38.0 (6-63) 58.8 (21-85) 19.2 (1-55) 152 (81.3%)
Cardiovascular
disease / stroke
126 (8.1%) 60/66
0.91
38.1 (7-70) 61.0 (34-88) 22.2 (2-58) 89 (70.6%)
Infections 67 (3.0%) 41/26
1.58
33.3 (17-58) 63.9 (35-92) 24.6 (2-57) 39 (58.2%)
Suicide 47 (3.0%) 24/23
1.04
32.2 (14-54) 46.4 (19-69) 12.3 (2-45) 35 (74.5%)
Other causesa 211 (13.4%) 126/85
1.48
36.0 (11-72) 59.0 (20-96) 21.5 (1-59) 140 (66.3%)
Unknownb 231 (14.7%) 133/98
1.36
34.3 (11-72) 54.2 (19-88) 19.2 (1–53) 173 (74.9%)
a Accidents, digestive diseases, respiratory diseases, neurological diseases other than MS, unspeciﬁed, and other causes.
b Unavailable death certiﬁcates.
MS = multiple sclerosis; F = female; M = male.
doi:10.1371/journal.pone.0132033.t002
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Table 3. Mortality rates and survival probabilities 25 years after MS clinical onset.
Subgroups Number of
deaths (%)
Death rate (per 1000
patient-years) [95% CI]
Probability of being alive 25 years after
MS clinical onset (%) [95% CI]
Adjusted odds
ratio [95% CI]
p-value
(Logrank test)
Overall 1,569 (5.7%) 3.73 [3.55–3.92] 89.6 [88.9–90.2] n.a. n.a.
Sex 10−4
Male 685 (8.6%) 5.53 [5.13–5.96] 84.9 [83.4–86.2] 1.67 [1.51–1.85]
Female 884 (4.5%) 2.98 [2.79–3.18] 91.7 [91.0–92.4] 1
Age at MS onset
(years)
10−4
<20 134 (4.9% 2.45 [2.07–2.90] 95.1 [93.8–96.2] 1
20–40 925 (5.1%) 3.23 [3.03–3.45] 91.4 [90.6–92.1] 1.81 [1.50–2.18]
40 510 (7.5%) 6.38 [5.85–6.96] 76.1 [73.3–78.6] 4.84 [3.94–5.94]
Initial course 10−4
Relapsing 1,137 (4.9%) 3.16 [2.98–3.34] 91.6 [90.9–92.2] 1
Progressive 430 (10.8%) 7.33 [6.67–8.06] 73.3 [74.7–79.6] 1.73 [1.53–1.95]
Year of onset Not included 10−4
<1980 327 (18.2%) 5.44 [5.04–5.89] 93.7 [92.8–94.5]
1980–1989 485 (9.1%) 4.05 [3.70–4.42] 88.2 [87.0–89.3]
1990–1999 380 (3.7%) 2.78 [2.51–3.07] n. a.
2000–2009 73 (0.8%) 1.52 [1.21–1.91] n. a.
MS duration
(years)
n. a. Not included 10−4
0–10 257 (2.6%) 1.11 [0.98–1.26]
10–20 543 (5.4%) 4.46 [4.10–4.85]
20–30 447 (8.9%) 9.27 [8.45–10.17]
30–40 216 (11.0%) 14.11 [12.35–16.12]
>40 106 (15.1%) 26.48 [21.89–32.03]
MS = multiple sclerosis; CI = conﬁdence interval; n.a. = not applicable
doi:10.1371/journal.pone.0132033.t003
Fig 2. Comparison of the survival in MS patients with the survival of the French general population.
Kaplan-Meier survival estimates according to time fromMS clinical onset (years). MS = Multiple Sclerosis.
doi:10.1371/journal.pone.0132033.g002
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7 years. Indeed, the observed median survival time was estimated to be around 53–54 years
fromMS onset, while the expected one in the French general population would have been
about 61 years. Similarly, respectively 60% and 70% of patients were still alive after 49 and 43–
44 years of MS duration, while these figures would have been observed in the French general
population after 56–57 and 51 years.
Different SMRs were observed across the 15 participating centers. In Rennes, the SMR was
1.99 [1.77-2.25]. In Lyon, which is the original EDMUS center and largest referral center for
MS in France, the SMR was 2.15 [1.98-2.34], and up to 2.78 [2.52–3.06] if considering historical
cohort only [22]. In Lorraine region, the SMR was surprisingly low, at 0.88 [0.73-1.05]—the
only one below 1 (but non significantly).
As shown in Table 4, excess mortality was higher in women than in men, and in patients
with earlier rather than later MS clinical onset, while death rates were lower in these subgroups.
On the opposite, patients with progressive onset had both higher mortality rates and higher
excess mortality than patients with relapsing onset.
If considering the overall death rate (1,569/364,700 = 4.3 per 1000 PY) in the subgroup of
patients without updated vital status (n = 4,607), a total of 241 deaths may be added, leading to
an overall number of 1,810 deaths and an overall SMR of 1.71 [1.63–1.79].
Discussion
To our knowledge, SURVIMUS is one of the largest studies of mortality in MS that have been
conducted so far, as more than 27,000 MS patients were included, representing about one third
of French prevalent cases.
In the present study, deaths were captured by linking the dataset to two national registers.
When the study started, only 500 deaths were notified in the EDMUS databases. This
Table 4. Overall and subgroup comparisons of mortality between MS patients and the French general population using Standardized Mortality
Ratios (SMR estimates with 95% CI, Poisson distribution).
Number of patients Observed deaths Expected deaths SMR [95% CI]
Overall 27,603 1,569 1060.64 1.48 [1.41–1.55]
Sex
Male 7,947 674 524.67 1.30 [1.21–1.40]
Female 19,656 885 535.97 1.65 [1.55–1.76]
Age at MS onset (years)
<20 2,746 134 62.19 2.15 [1.81–2.54]
20–40 18,089 925 581.39 1.59 [1.49–1.70]
 40 6,768 510 417.06 1.22 [1.12–1.33]
Initial MS course
Relapsing 22,438 1,137 797.23 1.43 [1.35–1.51]
Progressive 3,970 430 256.91 1.67 [1.52–1.84]
MS onset  2000 19,076 1,498 986.87 1.52 [1.44–1.60]
MS onset  1975 25,571 1,142 769.44 1.48 [1.40–1.57]
1st appointmenta  1992 19,540 679 596.40 1.14 [1.06–1.23]
MS duration  20 years 8,475 1,569 711.96 2.20 [2.10–2.31]
MS duration  10 years 17,874 1,569 973.04 1.61 [1.53–1.69]
Patients censored alive excluded 22,996 1,569 917.97 1.71 [1.63–1.79]
a 1st appointment = 1st appointment with a neurologist;
Abbreviations: CI = conﬁdence interval; MS = multiple sclerosis; SMR = standardized mortality ratio.
doi:10.1371/journal.pone.0132033.t004
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highlights the need for linkage to official national death registers in this kind of epidemiological
study, in order to avoid underestimating the event of interest. Even so, a number of patients
(n = 4,607) could not be traced in the French national register, either owing to a missing birth-
place or because they were born outside France, or there were suspected mistakes in the maiden
name (consistent with the high proportion of women). As this subgroup was older than the
group with known vital status, it may lead to under-estimation of mortality, but without chang-
ing the key finding of our study. Indeed, if assuming they have the same mortality risk as the
22,996 patients who were identified in the register, the excess mortality compared with the
French general population increased from 16% (from 1.48 to 1.71).
Our results confirm that MS patients are characterized by excess mortality, compared with
the general population, but to a lesser extent (SMR 1.48; sensitivity analysis 1.71) than reported
in previous studies (SMR up to 3) [2–4, 9, 10, 17]. We showed that life expectancy in patients is
probably reduced by 7 years. More especially, we were able to distinguish between two phases in
the risk of dying in MS patients: fromMS clinical onset to 20 years, the risk is not higher in MS
patients than in the French general population, whereas from 20 years of disease duration
onwards, excess mortality does exist, and can probably be linked to higher disability. This reduc-
tion in life expectancy is one of the lowest estimates in the literature, and similar to North Amer-
ican studies [4, 6, 18], and the observed 25-year survival probability is one of the highest
estimates. This may reveal an improvement in the survival of MS patients over time, as previ-
ously suggested [8]. However, we cannot assess how far, if at all, factors such as disease-modify-
ing drugs (DMDs) or multidisciplinary MS management account for this improvement. Indeed,
a long-term follow-up of a clinical trial has found an increased survival in early treatment group
compared to delayed treatment group [30]. DMDs were not assessed in our study because this
complex topic requires a specific design which takes into account lack of randomization in real-
life study. However, we should also remember that a proportion of 89% of patients alive at 25
years of disease duration was already found in a Turkish study [13] published in 1998, i.e. before
the treatment era.
We found that excess mortality was strongly correlated with disease duration, as the longer
the disease duration, the greater the probability of death. We can assume that the overall SMR
was lower than that of other series owing to the shorter disease duration of our MS population
(mean 15 years). This is consistent with results of the first French EDMUS-user centers. In
Rennes, the SMR was 1.99, that is much higher than the SMR (1.3) we had observed in our pre-
vious study [5], but the mean follow-up duration was also far longer (18 vs. 13 years). Similar
results were observed in Lyon (whole and historical cohort). The low value of SMR in Lorraine
region may be attributed to the recent nature of this MS population-based registry [31], mean-
ing that although they are now close to achieving the exhaustive registration of prevalent cases,
some patients have died before having the opportunity to be included in the database. By the
way, the risk of dying for a patient before enrollment in the EDMUS database may apply in all
the participating centers and can contribute to the lower excess mortality observed in the pres-
ent study compared with other series. We can wonder if disease duration might be considered
as a proxy of disability level (not available here), as disability was found as a prognostic factor
for death [32] and low disability level was shown to be associated with a low SMR [5, 6]. But
heterogeneity in the MS course is well-known, and many patients will live long lives without
life-threatening disability.
Finally, a selection bias in patients’ enrollment towards a less malign course or an earlier
diagnosis cannot be excluded too as the participating centers are considered as MS expert cen-
ters, as well as an immortal time bias (patients need to survive a sufficient amount of time to be
enrolled in the database) as discussed above.
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We observed that excess mortality was higher in patients who were young at MS onset and
in women, even though these two subgroups had lower mortality rates. The fact that observed
mortality may be low and excess mortality high suggests that excess mortality may be due to
MS and not attributable to other factors such as demographics. Regarding the 1,338 known
causes of death, MS was the underlying cause of death notified in 52.3% of deaths certificates,
followed by cancer (14.0%) and cardiovascular disease (9.4%), mostly consistent with the litera-
ture. We can assume that the MS category includes complications of MS such as sepsis, aspira-
tion pneumonia, and other events that are seen in individuals with severe disability. If
pneumonia (ICD-10 code J690), tetraplegia (G825), and paraplegia (G822) as underlying cause
were considered as MS, 18 cases would be added, leading to a proportion of deaths due to MS
of 53.7%. Cardiovascular deaths were not so frequent, in accordance with the low mean age of
the population at last information. The frequency of suicide (3.5%) was lower than in other
series [2, 9, 17, 33], but some of them have also included accidents in this category. We can sur-
mise that some of the deaths classified as accidental deaths or unspecified deaths were suicides.
When we included some potential hidden suicides, we obtained a total number of 79, leading
to a frequency of 5.9%. In the most recent studies, suicide was considered to be MS-related and
included in the MS cause category [8]. Had we done so, MS would have accounted for 55.8% to
58.2% of deaths.
Next steps will consist of a further analysis of causes of death, not just underlying, but also
contributory, and their combination. Moreover, attempts of defining “MS-related” death are
ongoing. Cause-specific mortality rates of the French general population will be used and
should help us to clarify the relationship between specific causes of death and excess mortality.
Moreover, we are currently collecting additional data for suicide cases, in order to look at socio-
economic characteristics (employment, marital status, etc.), mental health status, and trends
over time.
To conclude, the results of the SURVIMUS study show that there is a moderate decrease in
life expectancy for MS patients, and that the risk of dying is strongly correlated with disease
duration, and probably disability progression, highlighting the need for actions that can delay
disability progression. Even though excess mortality starts only after 20 years of disease dura-
tion, interventions such as DMTs or multidisciplinary care should be started as soon as possible
in the disease course in order to maximize their efficacy in slowing down disability progression
[34]. We now have access to precise and up-to-date reference data about survival in MS in
France, which is crucial for neurologists, patients, and their families.
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